Anti-B. anthracis protective antigen (PA) Recombinant Antibody (14B7) (CAT#: MRO-073CT)

Recombinant monoclonal antibody specifically binds to Bacillus anthracis protective antigen (PA), expressed in Chinese Hamster Ovary cells(CHO).


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Datasheet
  • MSDS
  • COA
Neut

Figure 1 Neutralization of lethal toxin activity by anti-PA MAbs.

Figure 1 Neutralization of lethal toxin activity by anti-PA MAbs.

Various concentrations of purified human (1303) and murine (1G3,14B7) MAbs were premixed with anthrax lethal toxin (400 ng PA and40 ng LF per ml) before addition to J774A.1 macrophages. Viability was determined after 3h of incubation. Values represent the means ofresults from duplicate wells of a representative experiment.

Vitale, L., Blanset, D., Lowy, I., O'Neill, T., Goldstein, J., Little, S. F., ... & Keler, T. (2006). Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infection and immunity, 74(10), 5840-5847.

FC

Figure 2 MAb 1303 does not block PA binding to cells.

Figure 2 MAb 1303 does not block PA binding to cells.

Flow cytometryof PA-FITC binding to human monocytes in the presence or absence ofanti-PA antibodies was analyzed. Anti-PA antibodies (14B7, 10 μg/ml;1303, 10 μg/ml) were preincubated with PA-FITC for 20min prior to incubation with monocytes for 1 h at ambient temperature. After washing, the cell-associated fluorescence was determined. The shaded histogram represents cells not exposed to PA-FITC.

Vitale, L., Blanset, D., Lowy, I., O'Neill, T., Goldstein, J., Little, S. F., ... & Keler, T. (2006). Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infection and immunity, 74(10), 5840-5847.


Specifications

  • Host Species
  • Human
  • Type
  • Human antibody
  • Species Reactivity
  • B. anthracis
  • Clone
  • 14B7
  • Applications
  • Neut, FC
  • Related Disease
  • Anthrax (Bacillus anthracis)

Applications

  • Application Notes
  • This antibody has been reported for use in Neutralization and Flow Cytometry.

Target

  • Alternative Names
  • PA; PA83; pag; PagA; Protective antigen; Bacillus anthracis; B. anthracis

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Clone 14B7"

See other products for "PA"

Chimeric Antibody

CAT Product Name Application Type
TAB-440CQ Anti-Bacillus Anthracis PA Recombinant Antibody (Obiltoxaximab) ELISA, IHC, FC, IP, IF, FuncS IgG1, κ

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for MRO-073CT. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare